RT Journal Article
SR Electronic
T1 New Life for Immunotoxin Cancer Therapy
JF Clinical Cancer Research
JO Clin Cancer Res
FD American Association for Cancer Research
SP 1055
OP 1058
DO 10.1158/1078-0432.CCR-15-1623
VO 22
IS 5
A1 Hassan, Raffit
A1 Alewine, Christine
A1 Pastan, Ira
YR 2016
UL http://clincancerres.aacrjournals.org/content/22/5/1055.abstract
AB Immunotoxins are targeted anticancer therapeutics that kill cancer cells using a cytotoxic bacterial toxin payload. Their development for use in solid tumor malignancies was delayed due to issues with their immunogenicity and limited therapeutic window. However, new research has rejuvenated the field. Coadministration with a lymphocyte-depleting regimen of pentostatin and cyclophosphamide can delay antidrug antibody formation, increasing the number of treatment cycles that patients can receive and resulting in durable responses in heavily pretreated patients. In addition, a new generation of immunotoxin molecules with reduced immunogenicity and nonspecific toxicity has been developed through protein engineering techniques, and one has recently entered the clinic. In preclinical studies in mouse models, these new agents are effective against many tumor types as single agents, and also produce synergistic antitumor responses in combination with chemotherapy. These new immunotoxins have renewed excitement in the field and may prove a promising addition to the targeted therapy repertoire. Clin Cancer Res; 22(5); 1055–8. ©2015 AACR.